| 1 |
35081280 | Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. | 2022 Jan 27 |
2 |
| 2 |
35156617 | Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. | 2022 Apr |
1 |
| 3 |
35373565 | Clinical settings with tofacitinib in ulcerative colitis. | 2022 Apr 4 |
2 |
| 4 |
35392018 | Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis. | 2022 Feb |
1 |
| 5 |
35484689 | Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. | 2022 Apr 28 |
1 |
| 6 |
35536531 | Tofacitinib enhances IGF1 via inhibiting STAT6 transcriptionally activated-miR-425-5p to ameliorate inflammation in RA-FLS. | 2022 May 10 |
2 |
| 7 |
33165509 | Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients. | 2021 May 17 |
1 |
| 8 |
33405424 | Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. | 2021 Oct 1 |
1 |
| 9 |
33484120 | High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF. | 2021 Apr 15 |
1 |
| 10 |
33495807 | Downregulation of miR‑409‑3p suppresses LPS‑induced inflammation in human bronchial epithelial cells through SOCS3/JAK1/STAT3 signaling: The implication for bronchopneumonia. | 2021 Mar |
1 |
| 11 |
33835018 | Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors. | 2021 Jul |
1 |
| 12 |
33899926 | Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis. | 2021 Aug |
2 |
| 13 |
34052462 | The JAK inhibitor Tofacitinib inhibits structural damage in osteoarthritis by modulating JAK1/TNF-alpha/IL-6 signaling through Mir-149-5p. | 2021 Oct |
2 |
| 14 |
34907436 | Trend in Prescription and Treatment Retention of Molecular-Targeted Drugs in 121,131 Japanese Patients With Rheumatoid Arthritis: A Population-Based Real-World Study. | 2021 Dec 15 |
2 |
| 15 |
31560043 | Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype. | 2020 Feb 11 |
1 |
| 16 |
31813060 | Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review. | 2020 Jan |
1 |
| 17 |
31916703 | Treatment of Multiorgan Sarcoidosis With Tofacitinib. | 2020 Feb |
1 |
| 18 |
31945470 | First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. | 2020 Sep |
4 |
| 19 |
32237087 | Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. | 2020 May |
1 |
| 20 |
32922513 | Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. | 2020 |
1 |
| 21 |
30734234 | Real-World Experience with Tofacitinib in IBD at a Tertiary Center. | 2019 Jul |
1 |
| 22 |
31284768 | Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. | 2019 Dec |
2 |
| 23 |
31285419 | IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs. | 2019 Jul 8 |
1 |
| 24 |
31780862 | Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis. | 2019 |
1 |
| 25 |
29205406 | Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. | 2018 Jan |
1 |
| 26 |
29352846 | The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes. | 2018 Jul-Aug |
2 |
| 27 |
29897007 | An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. | 2018 Oct |
1 |
| 28 |
30174394 | Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. | 2018 Sep-Oct |
1 |
| 29 |
28164724 | JAK inhibition in inflammatory bowel disease. | 2017 Jul |
2 |
| 30 |
28570653 | Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma. | 2017 |
1 |
| 31 |
28754958 | A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis. | 2017 Jul 28 |
1 |
| 32 |
29045207 | Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. | 2017 Oct 19 |
4 |
| 33 |
29268845 | [Inhibitory effect and mechanism of tofacitinib on the secretion of cytokines by T cells in human peripheral blood]. | 2017 Nov |
3 |
| 34 |
26932398 | Current concepts in the management of rheumatoid arthritis. | 2016 Mar |
2 |
| 35 |
27579831 | An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. | 2016 Sep |
2 |
| 36 |
27663846 | Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn's disease: a case report. | 2016 Sep 23 |
2 |
| 37 |
27855242 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). | 2016 Nov 17 |
1 |
| 38 |
26152731 | Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. | 2015 Sep |
1 |
| 39 |
24342887 | Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity. | 2014 Feb |
1 |
| 40 |
24624736 | [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)]. | 2014 Jan 22 |
1 |
| 41 |
23212593 | JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. | 2013 May |
2 |
| 42 |
23570265 | A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. | 2013 Jun |
1 |
| 43 |
22121136 | The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. | 2012 Mar |
4 |